Acorda Thera (ACOR) Posts Q3 Loss of $0.51, 8c Better than Estimates
More News related to ACOR
- Acorda Therapeutics to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Acorda Therapeutic (ACOR) volatility at 55 into extension of PDUFA
- Acorda Thera (ACOR) Posts Q3 Loss of $0.51, 8c Better than Estimates
- Acorda Therapeutics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/03: UBS (UBS), Yamana Gold (AUY), Archer-Daniels (ADM), Royal Caribbean (RCL), Marathon (MRO) Report
Acorda Therapeutics (NASDAQ: ACOR) reports Q3 loss of $0.51, 8 cents better than the analyst estimate of ($0.59). Revenue for the quarter was $15.21 million, which compares to the estimate of $14.22 million.
Related Categories
EarningsStocks Mentioned
+0.36Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
